A trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, with results showing that the new drug Xofluza is well tolerated in children with the flu.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
